NCT06154668View on ClinicalTrials.gov

Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients

RecruitingOBSERVATIONAL

Enrollment

707

Participants

Timeline

Start Date

January 17, 2024

Primary Completion Date

January 31, 2030

Study Completion Date

January 31, 2031

Conditions

Melanoma

Trial Locations (1)

38043

RECRUITING

CHU Grenoble Alpes, Grenoble

All Listed Sponsors

collaborator

Etablissement Français du Sang

OTHER

lead

University Hospital, Grenoble

OTHER

NCT06154668 - Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients | Biotech Hunter | Biotech Hunter